138 related articles for article (PubMed ID: 1966859)
1. Adjuvant formulations and their mode of action.
Allison AC; Byars NE
Semin Immunol; 1990 Sep; 2(5):369-74. PubMed ID: 1966859
[TBL] [Abstract][Full Text] [Related]
2. Immunological adjuvants: desirable properties and side-effects.
Allison AC; Byars NE
Mol Immunol; 1991 Mar; 28(3):279-84. PubMed ID: 1850114
[TBL] [Abstract][Full Text] [Related]
3. Immunological adjuvants and their modes of action.
Allison AC
Arch Immunol Ther Exp (Warsz); 1997; 45(2-3):141-7. PubMed ID: 9597079
[TBL] [Abstract][Full Text] [Related]
4. [Enhancement of the activity of hepatitis B virus vaccine by association with murabutide].
Audibert F; Przewlocki G; Lefrancier P; Choay J; Chedid L
C R Seances Acad Sci III; 1982 Nov; 295(10):611-4. PubMed ID: 6218866
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs.
Robuccio JA; Griffith JW; Chroscinski EA; Cross PJ; Light TE; Lang CM
Lab Anim Sci; 1995 Aug; 45(4):420-6. PubMed ID: 7474883
[TBL] [Abstract][Full Text] [Related]
6. Squalene and squalane emulsions as adjuvants.
Allison AC
Methods; 1999 Sep; 19(1):87-93. PubMed ID: 10525443
[TBL] [Abstract][Full Text] [Related]
7. [Use of muramyl dipeptides in models of synthetic vaccines].
Audibert F
Boll Ist Sieroter Milan; 1985; 64(2):95-102. PubMed ID: 3896261
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity.
Byars NE; Allison AC
Vaccine; 1987 Sep; 5(3):223-8. PubMed ID: 3499713
[TBL] [Abstract][Full Text] [Related]
9. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector.
Finerty S; Tarlton J; Mackett M; Conway M; Arrand JR; Watkins PE; Morgan AJ
J Gen Virol; 1992 Feb; 73 ( Pt 2)():449-53. PubMed ID: 1311367
[TBL] [Abstract][Full Text] [Related]
10. Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP).
Hornung RL; Longo DL; Gowda VL; Kwak LW
Ther Immunol; 1995 Feb; 2(1):7-14. PubMed ID: 7553072
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant activity of some nonpyrogenic hydrophobic analogues of muramyl dipeptide in enhancing the primary humoral and cell mediated immune responses in guinea pig model.
Saxena RP; Puri A; Saxena KC; Shukla R; Haq W; Rizvi SY; Kundu B; Mathur KB
Indian J Exp Biol; 1991 Feb; 29(2):111-5. PubMed ID: 1869292
[TBL] [Abstract][Full Text] [Related]
12. A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen.
Yang HZ; Xu S; Liao XY; Zhang SD; Liang ZL; Liu BH; Bai JY; Jiang C; Ding J; Cheng GF; Liu G
J Med Chem; 2005 Aug; 48(16):5112-22. PubMed ID: 16078831
[TBL] [Abstract][Full Text] [Related]
13. Immunoadjuvant activities of synthetic 6-O-acyl-N-acetylmuramyl-L-alanyl-D-isoglutamine with special reference to the effect of its administration with liposomes.
Kotani S; Kinoshita F; Morisaki I; Shimono T; Okunaga T; Takada H; Tsujimoto M; Watanabe Y; Kato K; Shiba T; Kusumoto S; Okada S
Biken J; 1977 Dec; 20(3-4):95-103. PubMed ID: 614856
[TBL] [Abstract][Full Text] [Related]
14. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity.
Allison AC; Byars NE
J Immunol Methods; 1986 Dec; 95(2):157-68. PubMed ID: 3540125
[TBL] [Abstract][Full Text] [Related]
15. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
Sanchez-Pescador L; Burke RL; Ott G; Van Nest G
J Immunol; 1988 Sep; 141(5):1720-7. PubMed ID: 2842401
[TBL] [Abstract][Full Text] [Related]
16. Persistent enhancement of cell-mediated and antibody immune responses after administration of muramyl dipeptide derivatives with antigen in metabolizable oil.
Carelli C; Audibert F; Chedid L
Infect Immun; 1981 Jul; 33(1):312-4. PubMed ID: 7263069
[TBL] [Abstract][Full Text] [Related]
17. Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use.
Morgan AJ; Allison AC; Finerty S; Scullion FT; Byars NE; Epstein MA
J Med Virol; 1989 Sep; 29(1):74-8. PubMed ID: 2555448
[TBL] [Abstract][Full Text] [Related]
18. Improvement of hepatitis B vaccine by the use of a new adjuvant.
Byars NE; Nakano G; Welch M; Lehman D; Allison AC
Vaccine; 1991 May; 9(5):309-18. PubMed ID: 1872014
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59.
Ott G; Barchfeld GL; Van Nest G
Vaccine; 1995 Nov; 13(16):1557-62. PubMed ID: 8578842
[TBL] [Abstract][Full Text] [Related]
20. Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection.
Byars NE; Fraser-Smith EB; Pecyk RA; Welch M; Nakano G; Burke RL; Hayward AR; Allison AC
Vaccine; 1994; 12(3):200-9. PubMed ID: 8165851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
